Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
| ▸ | FPR2 | P25090 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.49 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.49 |
| ▸ | KCNQ4 | P56696 | 1/20 | 0.49 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7407182 | 0.86 | SMN1; SMN2 (0.53) | CYP1A2CYP2C9CYP2C19SMN1; SMN2MAPT | |
| SCHEMBL12407109 | 0.86 | CYP1A2 (0.73) | CYP1A2CYP2C9CYP2C19SMN1; SMN2MAPT | |
| SCHEMBL15682730 | 0.85 | GPR35 (0.61) | SMN1; SMN2MAPTPOLBRAB9ANPC1 | |
| SCHEMBL9175285 | 0.84 | CYP1A2 (0.61) | CYP1A2CYP2C9CYP2C19SMN1; SMN2MAPT | |
| SCHEMBL6004344 | 0.84 | SMN1; SMN2 (0.73) | CYP1A2CYP2C9CYP2C19SMN1; SMN2MAPT | |
| SCHEMBL10629048 | 0.84 | MAPT (0.53) | SMN1; SMN2MAPTPOLBRAB9ANPC1 | |
| SCHEMBL28618912 | 0.84 | ALDH1A1 (0.59) | SMN1; SMN2MAPTPOLBRAB9ANPC1 | |
| SCHEMBL2765494 | 0.83 | CYP1A2 (0.59) | CYP1A2CYP2C9CYP2C19SMN1; SMN2RAB9A | |
| SCHEMBL1776718 | 0.82 | MAPT (0.48) | SMN1; SMN2MAPTPOLBRAB9ANPC1 | |
| SCHEMBL7555717 | 0.82 | CYP1A2 (0.58) | CYP1A2CYP2C9CYP2C19SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691850-B2 | Antibacterial agents | GLAXO GROUP LIMITED (GB) | 2010-04-06 | — | — | US | disclosed |
| EP-1796466-A4 | ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2009-09-02 | — | — | EP | disclosed |
| US-20070287701-A1 | 6-({[(1-{2-[6-(methyloxy)-1,5-naphthyridin-4-yl]ethyl}-3-pyrrolidinyl)methyl]amino}methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | SMITHKLINE BEECHAM CORPORATION | 2007-12-13 | — | — | US | disclosed |
| EP-1796466-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2007-06-20 | — | — | EP | disclosed |
| CN-1832922-A | Sulfonyl-substituted N- (biarylmethyl) aminocyclopropanecarboxamides | MERCK & CO INC (US) | 2006-09-13 | — | — | CN | disclosed |
| US-20060167087-A1 | Substituted aniline derivatives | H. LUNDBECK A/S (DK) | 2006-07-27 | — | — | US | disclosed |
| WO-2006002047-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2006-01-05 | — | — | WO | disclosed |
| EP-1606247-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. Lundbeck A/S (DK) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004080950-A1 | SUBSTITUTED ANILINE DERIVATIVES | H. LUNDBECK A/S (DK) | 2004-09-23 | — | — | WO | disclosed |
| US-6174839-B1 | AS HERBICIDE | NIHON BAYER AGROCHEM K.K. (JP) | 2001-01-16 | — | — | US | disclosed |
| US-5935907-A | HERBICIDES | NIHON BAYER AGROCHEM K.K. (JP) | 1999-08-10 | — | — | US | disclosed |
| EP-0869123-A2 | Phenylacetylene derivatives | NIHON BAYER AGROCHEM K.K. (JP) | 1998-10-07 | — | — | EP | disclosed |
| US-4859229-A | HERBICIDES | HOFFMANN-LA ROCHE INC. (US) | 1989-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287701-A1 | 6-({[(1-{2-[6-(methyloxy)-1,5-naphthyridin-4-yl]ethyl}-3-pyrrolidinyl)methyl]amino}methyl)-2H-pyrido[3,2-b][1,4]thiazin-3(4H)-one; bacterial infections; antibiotic resistance; Staphylococcus aureus, Streptococcus pneumoniae and pyogenes, Enterococcus; Haemophilus influenzae, Moraxella catarrhalis, E-coli | NPM1, TOP1, HMGB1 | CYP1A2 1472/4885CYP2C9 2340/4885CYP2C19 1388/4885 |
| US-20060167087-A1 | Substituted aniline derivatives | CYP3A43, UGT2B7, CYP3A7 | CYP1A2 9/4885CYP2C9 12/4885CYP2C19 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.